Tirofiban after clot-busting for stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had an ischemic stroke and received a standard dose of the clot-buster tenecteplase within 4.5 hours of symptoms starting.
- Your stroke symptoms are moderate — your NIHSS score is between 4 and 15, or you have trouble moving one arm or leg (score 2 or more).
- You can start the study drug (tirofiban or placebo) within 6 hours after the clot-buster.
- You had no major disability before the stroke (mRS score 0 or 1) and a head CT after clot-buster shows no bleeding in the brain.
- You do not have atrial fibrillation, a large area of brain damage on imaging, or recent bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether giving a medication called tirofiban directly into the artery (intra-arterially) after a successful clot removal can improve recovery after a stroke. Tirofiban helps prevent new clots from forming, which may reduce the chance of another stroke.
This trial tests whether starting tirofiban soon after tenecteplase can improve outcomes for people whose stroke symptoms temporarily get worse after treatment. It aims to see if the added medicine can reduce harmful clot-related changes after initial thrombolysis.
This study tests whether giving the blood-thinning drug tirofiban for a shorter or longer time after standard clot-busting treatment improves recovery from a stroke. It aims to find the best duration to prevent further damage while avoiding side effects.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This trial tests whether adding a medicine called tirofiban (which helps prevent blood clots) after standard stroke treatment can improve recovery in people who had a stroke due to a blocked large artery in the brain. It is for people who already received a clot-busting drug and a mechanical clot removal procedure, and who have not fully recovered.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.